NOVEMBER 14, 2023 TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases Read More →
JANUARY 9, 2023 TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases Read More →
MARCH 8, 2022 TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases Read More →
JANUARY 6, 2022 TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation Read More →
JUNE 22, 2021 TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases Read More →
